The most exciting trial that came out of the 2019 Gastrointestinal Cancer Symposium was the COMPASS trial, says Chung. COMPASS was a prospective trial that was conducted in Canada in which patients who were undergoing frontline therapy underwent concurrent tumor tissue biopsy and sequencing. Investigators did RNA sequencing as well as patient-derived organoids, results of which were received an average of 39 days later, says Chung. Watch here . . .
Vincent Chung, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, director of the Phase I Program, City of Hope, discusses the COMPASS trial in pancreatic cancer.